UK Markets closed

BRAIN Biotech AG (0RFI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
4.4097-0.7703 (-14.87%)
At close: 04:26PM BST
Full screen
Previous close5.1800
Open4.4097
Bid0.0000 x 0
Ask0.0000 x 0
Day's range4.4097 - 4.4097
52-week range4.4097 - 4.4097
Volume1,904
Avg. volumeN/A
Market cap79.778M
Beta (5Y monthly)1.35
PE ratio (TTM)N/A
EPS (TTM)-0.5780
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Change in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand

    EQS-News: BRAIN Biotech AG / Key word(s): Personnel/Strategic Company DecisionChange in the Executive Management Board of BRAIN Biotech AG, genome editing activities established under the Akribion Genomics brand 27.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement. Lukas Linnig stepping down as CFO. Michael Schneiders to become new CFO of BRAIN Biotech AG as of October 1st, 2022 Lukas Linnig and Dr. Michael Krohn to jointly lead Akribion Genomics activ

  • EQS Group

    BRAIN Biotech AG sells subsidiary L.A. Schmitt to a URI group company

    EQS-News: BRAIN Biotech AG / Key word(s): Disposal/Strategic Company DecisionBRAIN Biotech AG sells subsidiary L.A. Schmitt to a URI group company 26.09.2022 / 17:20 CET/CESTThe issuer is solely responsible for the content of this announcement. BRAIN Biotech AG further focusses business activities Transaction closed on September 26, 2022 URI group expands its network into European production Zwingenberg, September 26, 2022 – BRAIN Biotech AG has announced the sale of its subsidiary L.A. Schmitt

  • EQS Group

    BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting

    DGAP-News: BRAIN Biotech AG / Key word(s): Quarter Results/Quarterly / Interim StatementBRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting 29.08.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.BRAIN Biotech AG: On Track to Reach Financial Year 2021/22 Targets, 9M Reporting Positive topline growth trend confirmed by 29% expansion in Q3 9M Operating cash flow improved significantly from last year On track to reach full financ